ArticleArthritis research & therapy2025

Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study.

Rioko Hiura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.